RU94019984A - ПИРИДАЗИНЫ КАК ИНГИБИТОРЫ ИНТЕРЛЕЙКИН-1 β ПРЕОБРАЗУЮЩЕГО ФЕРМЕНТА, ФАРМКОМПОЗИЦИЯ НА ИХ ОСНОВЕ И ИХ ПРИМЕНЕНИЕ - Google Patents

ПИРИДАЗИНЫ КАК ИНГИБИТОРЫ ИНТЕРЛЕЙКИН-1 β ПРЕОБРАЗУЮЩЕГО ФЕРМЕНТА, ФАРМКОМПОЗИЦИЯ НА ИХ ОСНОВЕ И ИХ ПРИМЕНЕНИЕ

Info

Publication number
RU94019984A
RU94019984A RU94019984/04A RU94019984A RU94019984A RU 94019984 A RU94019984 A RU 94019984A RU 94019984/04 A RU94019984/04 A RU 94019984/04A RU 94019984 A RU94019984 A RU 94019984A RU 94019984 A RU94019984 A RU 94019984A
Authority
RU
Russia
Prior art keywords
alkyl
compounds
aryl
heteroaryl
interleukin
Prior art date
Application number
RU94019984/04A
Other languages
English (en)
Inventor
И.Долл Роланд
Us]
Дж.Шмидт Стэнли
У.Хойер Дентон
М.Росс Тина
М.Ринкер Джеймс
А.Этор Марк
Original Assignee
Стерлинг Уинтроп Инк. (US)
Стерлинг Уинтроп Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Стерлинг Уинтроп Инк. (US), Стерлинг Уинтроп Инк. filed Critical Стерлинг Уинтроп Инк. (US)
Publication of RU94019984A publication Critical patent/RU94019984A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
    • C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D237/10—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D237/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Предлагаются соединения формулы и их фармацевтически приемлемые соли:где R- галоген, связанная через кислород уходящая группа, включающая простой ароматический эфир, сложный ароматический эфир, алкил сульфонат, арил сульфонат, алкил фосфонат, арил фофонат, алкил фосфат или арил фосфат; Rявляется OR, NH (CHR)- COOR, NH (CHR)CON (R)R, N (R)Rили NH (CHR)OH; представляет H или алкил; представляет H, замещенный или незамещенный арил, гетероарил или алкил; Rи Rпредставляют независимо H, низший алкил, арил, гетероарил, аралкил, гетероаралкил или низший циклоалкил; m = 1 - 6; n = 2 - 6, фармацевтические композиции, содержащие соединения, и способ ингибирования активности интерлейкин-1β протеазы у млекопитающих, использующий соединения и композиции.

Claims (1)

  1. Предлагаются соединения формулы и их фармацевтически приемлемые соли:
    Figure 00000001
    где R1 - галоген, связанная через кислород уходящая группа, включающая простой ароматический эфир, сложный ароматический эфир, алкил сульфонат, арил сульфонат, алкил фосфонат, арил фофонат, алкил фосфат или арил фосфат; R2 является OR5, NH (CHR5)m - COOR5, NH (CHR5)m CON (R5)R6, N (R5)R6 или NH (CHR5)nOH; представляет H или алкил; представляет H, замещенный или незамещенный арил, гетероарил или алкил; R5 и R6 представляют независимо H, низший алкил, арил, гетероарил, аралкил, гетероаралкил или низший циклоалкил; m = 1 - 6; n = 2 - 6, фармацевтические композиции, содержащие соединения, и способ ингибирования активности интерлейкин-1β протеазы у млекопитающих, использующий соединения и композиции.
RU94019984/04A 1993-06-08 1994-06-07 ПИРИДАЗИНЫ КАК ИНГИБИТОРЫ ИНТЕРЛЕЙКИН-1 β ПРЕОБРАЗУЮЩЕГО ФЕРМЕНТА, ФАРМКОМПОЗИЦИЯ НА ИХ ОСНОВЕ И ИХ ПРИМЕНЕНИЕ RU94019984A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US7391493A 1993-06-08 1993-06-08
US073914 1993-06-08

Publications (1)

Publication Number Publication Date
RU94019984A true RU94019984A (ru) 1997-04-10

Family

ID=22116553

Family Applications (1)

Application Number Title Priority Date Filing Date
RU94019984/04A RU94019984A (ru) 1993-06-08 1994-06-07 ПИРИДАЗИНЫ КАК ИНГИБИТОРЫ ИНТЕРЛЕЙКИН-1 β ПРЕОБРАЗУЮЩЕГО ФЕРМЕНТА, ФАРМКОМПОЗИЦИЯ НА ИХ ОСНОВЕ И ИХ ПРИМЕНЕНИЕ

Country Status (18)

Country Link
US (3) US6121266A (ru)
EP (1) EP0628550B1 (ru)
JP (1) JPH0769894A (ru)
KR (1) KR950000673A (ru)
AT (1) ATE163412T1 (ru)
AU (1) AU693786B2 (ru)
CA (1) CA2125359A1 (ru)
CZ (1) CZ140194A3 (ru)
DE (1) DE69408598T2 (ru)
DK (1) DK0628550T3 (ru)
ES (1) ES2114654T3 (ru)
FI (1) FI942693A (ru)
HU (1) HUT67413A (ru)
IL (1) IL109918A0 (ru)
NO (1) NO306061B1 (ru)
NZ (1) NZ260698A (ru)
RU (1) RU94019984A (ru)
SK (1) SK69794A3 (ru)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
US6204261B1 (en) 1995-12-20 2001-03-20 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β Converting enzyme inhibitors
US6008217A (en) * 1995-12-20 1999-12-28 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
DE69408598T2 (de) 1993-06-08 1998-09-17 Vertex Pharmaceuticals Inc Cam Pyridazine als Interleukin-1-beta Verwandlungsenzym Inhibitoren
US5756466A (en) * 1994-06-17 1998-05-26 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5716929A (en) * 1994-06-17 1998-02-10 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1β converting enzyme
US5847135A (en) * 1994-06-17 1998-12-08 Vertex Pharmaceuticals, Incorporated Inhibitors of interleukin-1β converting enzyme
US6420522B1 (en) 1995-06-05 2002-07-16 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
EP0820464A2 (en) * 1995-03-31 1998-01-28 Takeda Chemical Industries, Ltd. Cysteine protease inhibitor
US5843904A (en) * 1995-12-20 1998-12-01 Vertex Pharmaceuticals, Inc. Inhibitors of interleukin-1βconverting enzyme
GB9715640D0 (en) * 1997-07-24 1997-10-01 M J Highway Technology Limited Road repair material
TWI241295B (en) * 1998-03-02 2005-10-11 Kowa Co Pyridazine derivative and medicine containing the same as effect component
JP2000247959A (ja) * 1999-02-26 2000-09-12 Kowa Co ピリダジン−３−オン誘導体及びこれを含有する医薬
EP2329842A3 (en) * 2000-05-12 2011-07-27 Immunex Corporation Interleukin-1 inhibitors in the treatment of diseases
US6664256B1 (en) 2000-07-10 2003-12-16 Kowa Co., Ltd. Phenylpyridazine compounds and medicines containing the same
EP1430033A4 (en) 2001-08-31 2004-12-15 Univ Northwestern PROTEIN KINASE ANTI-INFLAMMATORY AND INHIBITOR COMPOSITION AND METHOD OF USE
TWI314455B (en) * 2002-12-10 2009-09-11 Nippon Kayaku Kk 3-phenyl-cinnoline derivatives and anti-tumor agent containing the same
CN1759103A (zh) 2003-03-18 2006-04-12 兴和株式会社 水溶性苯基哒嗪衍生物及含有该衍生物的医药品
PA8619901A1 (es) 2003-12-12 2005-11-25 Wyeth Corp Quinolinas utiles en el tratamiento de enfermedades cardiovasculares
EP1720893B1 (en) * 2004-02-26 2014-08-13 Baylor Research Institute Compositions and methods for the systemic treatment of arthritis
WO2005115362A1 (en) * 2004-05-15 2005-12-08 Vertex Pharmaceuticals Incorporated Treating seizures using ice inhibitors
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
EP1812007B1 (en) 2004-11-02 2011-09-07 Northwestern University Pyridazine compounds and methods
MX2007005247A (es) 2004-11-02 2008-03-13 Univ Northwestern Compuestos de piridazina, composiciones y metodos.
WO2007127475A2 (en) * 2006-04-28 2007-11-08 Northwestern University Pyridazines for demyelinating diseases and neuropathic pain
WO2007127375A2 (en) 2006-04-28 2007-11-08 Northwestern University Formulations containing pyridazine compounds for treating neuroinflammatory diseases
WO2007127474A2 (en) 2006-04-28 2007-11-08 Northwestern University Compositions and treatments using pyridazine compounds and cholinesterase inhibitors
WO2012075393A2 (en) * 2010-12-02 2012-06-07 President And Fellows Of Harvard College Activators of proteasomal degradation and uses thereof
US9956260B1 (en) 2011-07-22 2018-05-01 The J. David Gladstone Institutes Treatment of HIV-1 infection and AIDS
KR102419136B1 (ko) 2017-06-15 2022-07-08 삼성전자주식회사 다채널 특징맵을 이용하는 영상 처리 장치 및 방법
AU2019302534A1 (en) * 2018-07-09 2021-01-28 Lieber Institute, Inc. Pyridazine compounds for inhibiting NaV1.8

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1603244A (en) * 1977-05-20 1981-11-18 Max Planck Gesellschaft Medicaments for the suppression of pathological processes
FR2511366A1 (fr) * 1981-08-11 1983-02-18 Sanofi Sa Nouveaux derives de la pyridazine, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent
US4590194A (en) * 1981-10-05 1986-05-20 Sterling Drug Inc. 3-[methyl or dimethyl)amino]-6-(pyridinyl)pyridazines and their cardiotonic use
GR860542B (en) * 1985-03-01 1986-06-25 Duphar Int Res Benzoyl urea derivatives having antitumor activity
US5055451A (en) * 1986-12-22 1991-10-08 Syntex Inc. Aryloxy and arylacyloxy methyl ketones as thiol protease inhibitors
DE4134467A1 (de) * 1991-10-18 1993-04-22 Thomae Gmbh Dr K Heterobiarylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5081145A (en) * 1990-02-01 1992-01-14 Merck Frosst Canada, Inc. Indole-2-alkanoic acids compositions of and anti allergic use thereof
AU7775991A (en) * 1990-04-04 1991-10-30 Immunex Corporation Interleukin 1beta protease
EP0519748B1 (en) * 1991-06-21 1998-09-02 Merck & Co. Inc. Peptidyl derivatives as inhibitors of interleukin-1B converting enzyme
DE69408598T2 (de) 1993-06-08 1998-09-17 Vertex Pharmaceuticals Inc Cam Pyridazine als Interleukin-1-beta Verwandlungsenzym Inhibitoren

Also Published As

Publication number Publication date
ES2114654T3 (es) 1998-06-01
FI942693A (fi) 1994-12-09
US20040110725A1 (en) 2004-06-10
NO942133L (no) 1994-12-09
IL109918A0 (en) 1994-10-07
SK69794A3 (en) 1995-02-08
CZ140194A3 (en) 1995-01-18
NZ260698A (en) 1996-09-25
EP0628550A2 (en) 1994-12-14
NO306061B1 (no) 1999-09-13
US6995261B2 (en) 2006-02-07
AU693786B2 (en) 1998-07-09
EP0628550B1 (en) 1998-02-25
DE69408598D1 (de) 1998-04-02
EP0628550A3 (en) 1995-01-18
HUT67413A (en) 1995-04-28
ATE163412T1 (de) 1998-03-15
DK0628550T3 (da) 1998-09-28
AU6455694A (en) 1994-12-15
DE69408598T2 (de) 1998-09-17
US6624166B1 (en) 2003-09-23
FI942693A0 (fi) 1994-06-08
NO942133D0 (no) 1994-06-08
US6121266A (en) 2000-09-19
HU9401714D0 (en) 1994-09-28
CA2125359A1 (en) 1994-12-09
JPH0769894A (ja) 1995-03-14
KR950000673A (ko) 1995-01-03

Similar Documents

Publication Publication Date Title
RU94019984A (ru) ПИРИДАЗИНЫ КАК ИНГИБИТОРЫ ИНТЕРЛЕЙКИН-1 β ПРЕОБРАЗУЮЩЕГО ФЕРМЕНТА, ФАРМКОМПОЗИЦИЯ НА ИХ ОСНОВЕ И ИХ ПРИМЕНЕНИЕ
ATE215078T1 (de) Verbessertes verfahren zum herstellen von geschützten 3,4-dihydroxybuttersäure estern
AU2507088A (en) Amino acid derivatives of phosphorus acids
ATE190312T1 (de) Ureido-derivate von naphtalenphosphonsäure und verfahren zu ihrer herstellung
FI954016A0 (fi) Uudet yhdisteet
ATE256667T1 (de) Verbindungen und deren verwendung zur behandlung von infektiösen erkrankungen
HUP9903421A2 (hu) Foszfonsav és foszfinsavszármazékok alkalmazása NAALADáz inhibitor hatású gyógyszerkészítmények előállítására
ATE37360T1 (de) Ester von imidazolaethanol.
ATE159512T1 (de) Prozess zur herstellung von beta-phenylisoserin und analogen verbindungen
ATE18549T1 (de) 1-carboxyalkanoylindolin-2-carbonsaeure-ester, verfahren zu ihrer herstellung, pharmazeutische praeparate enthaltend diese verbindungen, sowie ihre therapeutische verwendung.
AU6602594A (en) New phosphonic acid compounds, process for preparing them and pharmaceutical compositions containing them
DE3854109D1 (de) Verfahren zur herstellung von chinolincarbonsäuren.
RU94036445A (ru) Производные оксадиазолкарбонамида, способ их получения, промежуточные соединения, способ их получения, гербицидная композиция, способ борьбы с сорняками
ATE173922T1 (de) 2-arylpropionsäure-zubereitungen und verfahren zu ihrer herstellung
DE59712632D1 (de) Verfahren zur herstellung von 3-pyrrolin-2-carbonsäure-derivaten
DE3650106D1 (de) Verfahren zur Herstellung von Phosphonly-Hydroxyacyl-Prolinen.
ATE159517T1 (de) Verfahren zur herstellung von n-carbonylarylimine als zwischenprodukte in der synthese von therapeutisch aktiven taxol-derivaten
ATE236132T1 (de) Verfahren zur herstellung von 1,3-diaza- spiro(4.4)non-1-en-4-on derivaten und 1-cyano-1- acylaminocyclopentan zwischenprodukte
ATE189886T1 (de) Synthese von carbonsäurederivaten
DK601483D0 (da) Benzhydrylpiperazinderivater
ATE263766T1 (de) Verfahren zur synthese von carbapenem- zwischenprodukten
TH25468EX (th) การยับยั้งฟอสฟาติดิลไอโนซิทอล 3-ไดเนสด้วยวอร์ทแมนนิล และอนาลอคของมัน
ATE226942T1 (de) Verfahren zur herstellung von 1,3-diaza- spiro(4.4)non-1-en-4-on derivaten und 1-cyano-1- acylamino-cyclopentan zwischenprodukten